Allergan Unlimited Company, formerly Allergan Limited, is an Ireland-based pharmaceutical company. The Company is focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world. The Company's products primarily focus on four key therapeutic areas, including medical aesthetics, eye care, central nervous system and gastroenterology.

Employees

Sector

Pharmaceuticals

More about the company

04-07	Allergan Aesthetics Opens New Ami Training Center in Austin	CI
03-31	Allergan Aesthetics Announces Fourth Annual CoolMonth With Deals On CoolSculpting	CI

Market Cap	63.66B 55.76B 51.46B 47.54B 90.22B 6,082B 91.87B 617B 240B 2,982B 239B 234B 10,350B	P/E 2018	-8.76x	P/E 2019	-11.9x
Enterprise Value	80.96B 70.92B 65.44B 60.47B 115B 7,736B 117B 784B 305B 3,793B 304B 297B 13,164B	EV / Sales 2018	4.24x	EV / Sales 2019	4.98x
Free-Float	99.9%	Yield 2018	2.15%	Yield 2019	1.55%

04-07	Allergan Aesthetics Opens New Ami Training Center in Austin	CI
03-31	Allergan Aesthetics Announces Fourth Annual CoolMonth With Deals On CoolSculpting	CI
03-30	Allergan Aesthetics Presents Findings on Safety and Efficacy of Repeat Trenibote Treatments and Data on Medical Weight Loss Aesthetics Patient Behaviors At the 2026 American Academy of Dermatology Meeting	CI
03-19	Allergan Aesthetics Reveals Evolution in Approach to Modern Aesthetic Treatments with Comprehensive Global Survey and New Educational Solutions	CI
03-04	Allergan Aesthetics Shares Medical Weight Loss Data and the Changing Profile of Patients	CI
11-12	Allergan Aesthetics Unveils New Data at 2025 American Society for Dermatologic Surgery Annual Meeting Showcasing Transformative Innovation and Portfolio Excellence	CI
25-09-25	AllAllergan Aesthetics to Showcase Multimodal Treatment Approach and Continued Commitment to Skin Quality At AMWC Dubai	CI
25-08-19	Allergan Aesthetics Unveils Its Newest Hydration Hero	CI
25-06-30	U.S. Food and Drug Administration Accepts for Review Allergan Aesthetics Premarket Approval Application for Skinvive by Juvederm for the Improvement of Neck Appearance	CI
25-02-12	Allergan Aesthetics to Launch Three New Training Centers in the U.S. Expanding Access to High Quality Aesthetics Training	CI
24-10-18	BOTOX® Cosmetic (onabotulinumtoxinA) Receives FDA Approval for Moderate to Severe Vertical Bands Connecting the Jaw and Neck (Platysma Bands)	CI
24-08-27	Allergan Aesthetics Announces the Launch of Its Next Generation Hydration Product: Skinmedica HA5 Hydra Collagen Replenish + Restore Hydrator	CI
24-06-27	Allergan Aesthetics Debuts Alle Payment Plans	CI

24-04-01	Court Dismisses Class Action Against Biopharmaceutical Company For Failing To Disclose Progress Of Competitor; Second Circuit Affirms Dismissal Of Putative Class Action Against Allergan; Eleventh Circuit Affirms That "Toxic" Lender Qualified As A "Dealer" Under The Exchange Act Due To High-Volume Trading; Delaware Court Of Chancery Invalidates Governance Rights In Stockholder Agreement	AQ
22-04-20	Allergan, an AbbVie Company, to Present New Data from its Eye Care Portfolio at the 2022 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting	AQ
22-04-06	Allergan, an AbbVie Company, Announces Positive Topline Phase 3 Results Evaluating Investigational Twice-Daily Administration of VUITY 1.25% in Adults with Age-Related Blurry Near Vision	AQ
22-03-22	AbbVie and Allergan Aesthetics to Present New Research Across Dermatology Portfolio at 2022 AAD Annual Meeting	AQ
21-12-10	Allergan - VUITY 1.25%, the First and Only FDA-Approved Eye Drop to Treat Age-Related Blurry near Vision, is Now Available	AQ

21-04-20	Planète Bourse : La revue de presse du mardi 20 avril 2021
20-05-07	EN DIRECT DES MARCHES : Air France KLM, ArcelorMittal, Legrand, Natixis, Peugeot, Eurofins, Zalando, Facebook...
20-05-07	La Chine repart, mais Washington veille
20-05-06	EN DIRECT DES MARCHES : Danone, Sanofi, Crédit Agricole, Arkema, Neoen, Eurofins, BMW, Novo Nordisk...
20-05-06	Trump franchit le Rubicon

Actavis PLC Stock NYSE

Stocks

IE00BD1NQJ95

Pharmaceuticals

Valuation: Actavis PLC

Latest news : Actavis PLC

Press Releases: Actavis PLC

News in other languages: Actavis PLC

Managers and Directors: Actavis PLC

Other Pharmaceuticals

Financials

Company Profile

Manager	Title	Age	Since
Alex Thurman DFI	Director of Finance/CFO	56	2016-11-30
Robert Michael PSD	President	55	2020-05-07

Director	Title	Age	Since
Robert Michael BRD	Director/Board Member	55	2020-05-07
Scott Reents BRD	Director/Board Member	-	2020-05-07
Ryan Quigley BRD	Director/Board Member	-	2020-05-07

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ELI LILLY AND COMPANY	-1.60%	+1.37%	+57.31%	+168.94%	1,102B
JOHNSON & JOHNSON	-1.44%	+3.71%	+69.64%	+65.40%	643B
ABBVIE INC.	-0.75%	+0.44%	+34.70%	+86.52%	450B
ROCHE HOLDING AG	-1.35%	+0.63%	+30.26%	+26.28%	336B
ASTRAZENECA PLC	-0.86%	+0.99%	+39.36%	+40.85%	298B
NOVARTIS AG	-0.71%	-0.54%	+28.98%	+48.27%	288B
NOVO NORDISK A/S	-1.31%	+2.72%	-26.76%	-39.82%	222B
AMGEN INC.	-0.03%	+1.62%	+25.62%	+68.30%	199B
GILEAD SCIENCES, INC.	-0.40%	+7.50%	+21.51%	+82.50%	169B
Average	-0.72%	+2.47%	+31.18%	+60.81%	411.78B
Weighted average by Cap.	-0.41%	+2.14%	+42.25%	+86.55%

	2018	2019
Net sales	15.79B 13.83B 12.76B 11.79B 22.37B 1,508B 22.78B 153B 59.51B 740B 59.28B 57.98B 2,567B	16.09B 14.09B 13B 12.02B 22.8B 1,537B 23.22B 156B 60.65B 754B 60.41B 59.09B 2,616B
Net income	-5.1B -4.46B -4.12B -3.81B -7.22B -487B -7.35B -49.37B -19.21B -239B -19.14B -18.72B -829B	-5.27B -4.62B -4.26B -3.94B -7.47B -504B -7.61B -51.06B -19.87B -247B -19.79B -19.36B -857B
Net Debt	21.89B 19.17B 17.69B 16.35B 31.02B 2,092B 31.59B 212B 82.51B 1,026B 82.2B 80.4B 3,559B	17.3B 15.16B 13.99B 12.92B 24.52B 1,653B 24.97B 168B 65.23B 811B 64.98B 63.56B 2,814B

End-of-day quote NYSE Other stock markets
- ^USD	-